β1- and β2-Adrenoceptor polymorphisms and cardiovascular diseases

Fundamental and Clinical Pharmacology

Volumn 22, Issue 2, 2008, Pages 107-125

  Brodde, Otto Erich ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

adrenoceptor blocker; 1 adrenoceptor polymorphisms; 2 adrenoceptor polymorphisms; Cardiovascular system; Chronic heart failure; Hypertension

Indexed keywords

ADRENALIN; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DOBUTAMINE; ISOPRENALINE; METOPROLOL; NORADRENALIN; PHENYLEPHRINE; PLACEBO; SALBUTAMOL; SALMETEROL; TERBUTALINE;

ANGINA PECTORIS; ASTHMA; BRONCHUS MUSCLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DNA POLYMORPHISM; DOWN REGULATION; DRUG EFFECT; DRUG MEGADOSE; EXERCISE; GENE DELETION; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; HYPERTENSION; LOW DRUG DOSE; NONHUMAN; PATIENT CARE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR SMOOTH MUSCLE; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; PROGNOSIS;

ANIMALS; CARDIOVASCULAR DISEASES; HAPLOTYPES; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2;

EID: 40949113720     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00557.x     Document Type: Review

References (172)

1. 1-adrenoceptor: identification and rapid screening assay. Lancet (1999) 353 897.
2. 1- adrenergic receptor. J. Biol. Chem. (1999) 274 12670 12674.
3. 1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. J. Mol. Cell. Cardiol. (1999) 31 1025 1032.
4. 1-adrenergic receptor associated with survival in patients with heart failure. Eur. Heart J. (2000) 21 1853 1858.
5. 2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell Mol. Biol. (1993) 8 334 339.
6. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J. Biol. Chem. (1993) 268 23116 23121.
7. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry (1994) 33 9414 9419.
8. 1-adrenergic receptor. Proc. Natl. Acad. Sci. U.S.A. (1987) 84 7920 7924.
9. 1-adrenoceptor. Br. J. Clin. Pharmacol. (2004) 60 235 243.
10. Taylor M.R., Bristow M.R. The emerging pharmacogenomics of the β-adrenergic receptors. Congest. Heart Fail. (2004) 10 281 288.
11. Johnson J.A., Terra S.G. β-Adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics. Pharm. Res. (2002) 19 1779 1787.
12. Small K.M., McGraw D.W., Liggett S.B. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu. Rev. Pharmacol. Toxicol. (2003) 43 381 411.
13. Kirstein S.L., Insel P.A. Autonomic nervous system pharmacogenomics: a progress report. Pharmacol. Rev. (2004) 56 31 52.
14. Leineweber K., Büscher R., Bruck H., Brodde O.-E. β-Adrenoceptor polymorphisms. Naunyn-Schmiedebergs Arch. Pharmacol. (2004) 369 1 22.
15. 1-adrenergic receptor affect agonist-promoted trafficking. J. Cardiovasc. Pharmacol. (2002) 39 155 160.
16. 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J. Biol. Chem. (2002) 277 30429 30435.
17. 2-adrenergic receptor signaling. J. Biol. Chem. (2003) 278 10784 10789.
18. 1-adrenoceptors. Br. J. Pharmacol. (2004) 142 51 56.
19. Sandilands A., Yeo G., Brown M.J., O'Shaughnessy K.M. Functional responses of human β1 adrenoceptors with defined haplotypes for the common 389R>G and 49S>G polymorphisms. Pharmacogenetics (2004) 14 343 349.
20. 1-Adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat. Med. (2003) 9 1300 1305.
21. 1-adrenoceptors in isolated human atrial myocardium. Br. J. Pharmacol. (2003) 138 386 392.
22. 1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc. Natl. Acad. Sci. U.S.A. (2006) 103 11288 11293.
23. 1-adrenergic receptor polymorphisms in human right atrium in vitro. J. Am. Coll. Cardiol. (2002) 40 1275 1282.
24. 1-adrenergic receptor gene polymorphism and human fat cell lipolysis. Int. J. Obes. (2001) 25 1599 1603.
25. 1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J. Clin. Invest. (2007) 117 229 235.
26. McDevitt D.G. In vivo studies on the function of cardiac β-adrenoceptors in man. Eur. Heart J. (1989) 10 (Suppl. B) 22 28.
27. 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol. Rev. (1991) 43 203 242.
28. Brodde O.-E. Beta-adrenoceptors in cardiac disease. Pharmacol. Ther. (1993) 60 405 430.
29. 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics (2001) 11 191 197.
30. 1-adrenoceptor polymorphism in humans. Pharmacogenetics (2001) 11 199 205.
31. 1- adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade. Clin. Pharmacol. Ther. (2003) 73 366 371.
32. 1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin. Pharmacol. Ther. (2003) 74 372 379.
33. 1-adrenoceptor gene and aerobic power in coronary artery disease. Eur. Heart J. (2006) 27 808 816.
34. 1-adrenoceptor and α-subunit of G protein on heart rate and blood pressure during exercise test. The Finnish Cardiovascular Study. J. Appl. Physiol. (2006) 100 507 511.
35. 1-adrenoceptor polymorphism does not affect cardiac effects of exercise after parasympathetic inhibition by atropine. Pharmacogenet. Genomics (2006) 16 9 13.
36. 1-adrenoceptor gene polymorphism determines contractile response to catecholamines. Pharmacogenetics (2004) 14 711 716.
37. 1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J. Am. Coll. Cardiol. (2005) 46 2111 2115.
38. 1-adrenoceptor polymorphism. Naunyn-Schmiedebergs Arch. Pharmacol. (2007) 375 303 309.
39. LaRosee K., Huntgeburth M., Rosenkranz S., Schnabel P. Arg389Gly-Polymorphismus des β1-Adrenozeptors: Unterschiedliche Effekte von Metoprolol in Abhängigkeit vom Genotyp. Z. Kardiol. (2003) 92 (Suppl. 1 I/191 (Abstract).
40. 1-adrenergic receptor gene and hypertension. Circulation (2001) 104 187 190.
41. 1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. Am. J. Cardiol. (2001) 88 1034 1037.
42. McCaffery J.M., Pogue-Geile M.F., Ferrell R.E., Petro N., Manuck S.B. Variability within α- and β-adrenoreceptor genes as a predictor of cardiovascular function at rest and in response to mental challenge. J. Hypertens. (2002) 20 1105 1114.
43. Swan L., Birnie D.H., Padmanabhan S., Inglis G., Connell J.M.C., Hillis W.S. The genetic determination of left ventricular mass in healthy adults. Eur. Heart J. (2003) 24 577 582.
44. Stanton T., Inglis G.C., Padmanabhan S., Dominiczak A.F., Jardine A.G., Connell J.M.C. Variation at the beta-1 adrenoceptor gene locus affects left ventricular mass in renal failure. J. Nephrol. (2002) 15 512 518.
45. Shioji K., Kokubo Y., Mannami T. et al. Association between hypertension and the α-adducin, β1-adrenoreceptor, and G-protein β3subunit genes in the Japanese population; the Suita study. Hypertens. Res. (2004) 27 31 37.
46. Filigheddu F., Reid J.E., Troffa C. et al. Genetic polymorphisms of the β-adrenergic system: association with essential hypertension and response to β-blockade. Pharmacogenomics J. (2004) 4 154 160.
47. Ranade K., Jorgenson E., Sheu W.H.-H. et al. A polymorphism in the β1 adrenergic receptor is associated with resting heart rate. Am. J. Hum. Genet. (2002) 70 935 942.
48. 1-adrenoceptor does not influence blood pressure or heart rate response to β-blockade in hypertensive subjects. Clin. Sci. (2000) 99 233 238.
49. 1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther. (2003) 74 44 52.
50. 1-adrenergic receptor blockade in patients with essential hypertension. Clin. Cardiol. (2004) 27 347 350.
51. 1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin. Pharmacol. Ther. (2006) 80 23 32.
52. Leimbach W.N., Wallin G., Victor R., Aylward P.E., Sundlof G., Mark L. Direct evidence from intraneuronal recordings for increased central sympathetic outflow in patients with heart failure. Circulation (1986) 73 913 919.
53. Francis G.S., Cohn J.N. The autonomic nervous system in congestive heart failure. Annu. Rev. Med. (1986) 37 235 247.
54. Cohn J.N. Abnormalities of peripheral sympathetic nervous system control in congestive heart failure. Circulation (1990) 82 (Suppl. I) I-59 I-67.
55. Esler M., Kaye D., Lambert G., Esler D., Jennings G. Adrenergic nervous system in heart failure. Am. J. Cardiol. (1997) 80 7L 14L.
56. 1) in the human heart. J. Am. Coll. Cardiol. (2002) 40 1459 1465.
57. Port J.D., Bristow M.R. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J. Mol. Cell. Cardiol. (2001) 33 887 905.
58. Lohse M.J., Engelhardt S., Eschenhagen T. What is the role of the β-adrenergic signaling in heart failure? Circ. Res. (2003) 93 896 906.
59. Hata J.A., Williams M.L., Koch W.J. Genetic manipulation of myocardial β-adrenergic receptor activation and desensitization. J. Mol. Cell. Cardiol. (2004) 37 11 21.
60. Brodde O.-E., Michel M.C. Adrenergic and muscarinic receptors in the human heart. Pharmacol. Rev. (1999) 51 651 689.
61. Brodde O.-E., Leineweber K. Autonomic receptor systems in the failing and aging human heart: similarities and differences. Eur. J. Pharmacol. (2004) 500 167 176.
62. 1-adrenergic receptor is associated with effective β-blocker dose in dilated cardiomyopathy. Clin. Pharmacol. Ther. (2005) 78 221 231.
63. Iwai C., Akita H., Kanazawa K. et al. Arg389Gly polymorphism of the human β1-adrenergic receptor in patients with nonfatal myocardial infarction. Am. Heart J. (2003) 146 106 109.
64. 2C- adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. (2002) 347 1135 1142.
65. 2-adrenoceptor polymorphisms in heart failure: a case control study. Eur. Heart J. (2004) 25 1534 1541.
66. 1Arg389 and the risk of heart failure in the Japanese population. Br. J. Clin. Pharmacol. (2005) 60 414 417.
67. Metra M., Zani C., Covolo L. et al. Role of β1- and α2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study. Eur. J. Heart Fail. (2006) 8 131 135.
68. White H.L., Maqbool A., McMahon A.D. et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy. Eur. Heart J. (2002) 23 1087 1092.
69. Kanki H., Yang P., Xie H.-G., Kim R.B., George A.L., Jr., Roden D.M. Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. J. Cardiovasc. Electrophysiol. (2002) 13 252 256.
70. Iwai C., Akita H., Shiga N. et al. Suppressive effect of the Gly389 allele of the beta1-adrenergic receptor gene on the occurrence of ventricular tachycardia in dilated cardiomyopathy. Circ. J. (2002) 66 723 728.
71. De Groote P., Lamblin N., Helbecque N. et al. The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure. Eur. J. Heart Fail. (2005) 7 966 973.
72. Forleo C., Resta N., Sorrentino S. et al. Association of β-adrenergic receptor polymorphisms and progression of heart failure in patients with idiopathic dilated cardiomyopathy. Am. J. Med. (2004) 117 451 458.
73. 2- adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am. J. Cardiol. (2007) 99 250 255.
74. 1-adrenergic receptor predict exercise capacity in heart failure. Am. Heart J. (2002) 144 840 846.
75. Sandilands A.J., Parameshwar J., Large S., Brown M.J., O'Shaughnessy K.M. Confirmation of a role for the 389R>G β-1 adrenoceptor polymorphism on exercise capacity in heart failure. Heart (2005) 91 1613 1614.
76. 2- Adrenergic receptor subtypes - novel functions uncovered by gene-targeted mouse models. Biol. Cell (2004) 96 343 348.
77. Philipp M., Hein L. Adrenergic receptor knockout mice: distinct functions of 9 adrenergic receptor subtypes. Pharmacol. Ther. (2004) 101 65 74.
78. 2C-adrenergic receptor confers impaired coupling to multiple effects. J. Biol. Chem. (2000) 275 23059 23064.
79. 1Arg389 adrenergic polymorphisms are not associated with reduced left ventricular ejection fraction or increased left ventricular volume. J. Am. Coll. Cardiol. (2007) 49 274 276.
80. Bristow M.R. β-Adrenergic receptor blockade in chronic heart failure. Circulation (2000) 101 558 569.
81. Brodde O.-E. β-adrenoceptor blocker treatment and the cardiac β-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. Naunyn-Schmiedebergs Arch. Pharmacol. (2007) 374 361 372.
82. Hunt S.A., Baker D.W., Chin M.H. et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure) developed in collaboration with the International Society of Heart and Lung Transplantation endorsed by the Heart Failure Society of America. J. Am. Coll. Cardiol. (2001) 38 2103 2113.
83. 1-adrenoceptors. Proc. Aust. Health Med. Res. Congr. (2006 248 (Abstract).
84. 1-Adenergic receptor polymorphisms and left ventricular remodeling changes in response to β-blocker therapy. Pharmacogenet. Genomics (2005) 15 227 234.
85. De Groote P., Helbecque N., Lamblin N. et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet. Genomics (2005) 15 137 142.
86. White H.L., De Boer R.A., Maqbool A. et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur. J. Heart Fail. (2003) 5 463 468.
87. 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc. Natl. Acad. Sci. U.S.A. (1987) 84 46 50.
88. 2-adrenoceptor polymorphisms: relation between in vitro and in vivo phenotypes. Life Sci. (2004) 74 2803 2814.
89. 2-Adrenoceptor gene polymorphisms. Pharmacogenet. Genomics (2005) 15 267 275.
90. 2- adrenergic receptor gene. Br. J. Pharmacol. (1999) 126 841 844.
91. McGraw D.W., Forbes S.L., Kramer L.A., Liggett S.B. Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J. Clin. Invest. (1998) 102 1927 1932.
92. 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. (1996) 93 10483 10488.
93. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. U.S.A. (2000) 97 10483 10488.
94. 2-Adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin. Exp. Allergy (1998) 28 442 448.
95. 2-adrenoceptors in human atrial myocardium from nonfailing and failing hearts, consistent with Gs coupling but not with Gi coupling. Naunyn-Schmiedebergs Arch. Pharmacol. (2007) 375 11 28.
96. 2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. Pharmacogenetics (2000) 12 347 353.
97. 2 adrenoceptor gene Thr164Ile polymorphism on human adipose tissue lipolytic function. Br. J. Pharmacol. (2001) 133 708 712.
98. 2-adrenoceptor on the effects of β-adrenoceptor agonists on human lung mast cells. Int. Immunopharmacol. (2003) 3 91 95.
99. Lipworth B., Koppelman G.H., Wheatley A.P. et al. Aβ2 Adrenoceptor promoter polymorphisms: extended haplotypes and functional effects in peripheral blood mononuclear cells. Thorax (2002) 57 61 66.
100. 2-Adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am. Heart J. (2000) 139 537 542.
101. 2-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional responses in vivo. Pharmacogenetics (2003) 13 59 66.
102. 2-adrenoceptor polymorphisms cause increased forearm blood flow responses to mental stress and handgrip in humans. J. Appl. Physiol. (2005) 98 787 794.
103. 2-adrenergic receptor polymorphism alters the cardiac output response to isometric exercise. J. Appl. Physiol. (2005) 99 1776 1781.
104. 2-adrenergic receptor polymorphism is associated with altered cardiovascular responses to isometric exercise. Physiol. Genomics (2004) 16 323 328.
105. 2-adrenoceptors. Circulation (2001) 103 1048 1050.
106. 2-adrenoceptor exhibits blunted desensitization of cardiac functional responses in vivo. Am. J. Physiol. Heart Circ. Physiol. (2003) 285 H2034 H2038.
107. Barbato E., Penicka M., Delrue L. et al. Thr164Ile polymorphism of β2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy. Heart (2007) 93 856 861.
108. Gratze G., Fortin J., Labugger R. et al. β-2 Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension (1999) 33 1425 1430.
109. 2-adrenoreceptors on haemodynamic responses to adrenaline. Clin. Sci. (2003) 104 509 520.
110. 2- Adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension (2000) 36 371 375.
111. 2-Adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans. J. Physiol. (2003) 546 583 589.
112. 2-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl. J. Med. (2001) 345 1030 1035.
113. 2- adrenergic receptor gene haplotypes and venodilation in vivo. Clin. Pharmacol. Ther. (2005) 78 232 238.
114. 2-Adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. Pharmacogenetics (2004) 14 517 522.
115. 2-adrenergic receptor down-regulation. Clin. Pharmacol. Ther. (2003) 74 253 263.
116. 2 adrenoceptor polymorphism. Thorax (2000) 55 762 767.
117. Israel E., Chinchilli V.M., Ford J.G. et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial. Lancet (2004) 364 1505 1512.
118. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. (2000) 162 75 80.
119. 2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax (2006) 61 940 944.
120. Wechsler M.E., Lehman E., Lazarus S.C. et al. β-Adrenergic receptor polymorphisms and response to salmeterol. Am. J. Respir. Crit. Care Med. (2006) 173 519 526.
121. 2-adrenergic receptors: relevance to asthma. J. Allergy Clin. Immunol. (2000) 105 S487 S492.
122. Migita O., Noguchi E., Jian Z. et al. ADRB2 polymorphisms and asthma susceptibility: transmission disequilibrium test and meta-analysis. Int. Arch. Allergy Immunol. (2004) 134 150 157.
123. Contopoulos-Ioannidis D.G., Manoli E.N., Ioannidis J.P.A. Meta-analysis of the association of β2-adrenergic receptor polymorphisms with asthma phenotypes. J. Allergy Clin. Immunol. (2005) 115 963 972.
124. 2-adrenoceptor polymorphisms and asthma: a HuGE review. Am. J. Epidemiol. (2005) 162 201 211.
125. Sayers I., Hall I.P. Pharmacogenetic approaches in the treatment of asthma. Curr. Allergy Asthma Rep. (2005) 5 101 108.
126. 2-adrenergic receptor polymorphisms in asthma. Curr. Opin. Pulm. Med. (2006) 12 12 17.
127. Taylor D.R. Pharmacogenetics of β2-agonist drugs in asthma. Clin. Rev. Allergy Immunol. (2006) 31 247 258.
128. Michel M.C., Brodde O.-E., Insel P.A. Peripheral adrenergic receptors in hypertension. Hypertension (1990) 16 107 120.
129. Feldman R.D., Gros R. Impaired vasodilator function in hypertension: the role of alterations in receptor-G protein coupling. Trends Cardiovasc. Med. (1998) 8 297 305.
130. Wood A.J.J. Variability in β-adrenergic receptor response in the vasculature: role of receptor polymorphism. J. Allergy Clin. Immunol. (2002) 110 S318 S321.
131. 2- adrenoceptor gene and hypertension: is it the promoter or the coding region or neither? J. Hypertens. (2006) 24 1003 1007.
132. 2-adrenergic receptor gene as susceptibility locus for human hypertension. Circulation (2000) 101 2877 2882.
133. Snieder H., Dong Y., Barbeau P. et al. β2-Adrenergic receptor gene and resting hemodynamics in European and African American youth. Am. J. Hypertens. (2002) 15 973 979.
134. 2-adrenoceptor. Hypertension (1997) 30 773 776.
135. Pereira A.C., Floriano M.S., Mota G.F. et al. β2 adrenoceptor functional gene variants, obesity, and blood pressure level interactions in the general population. Hypertension (2003) 42 685 692.
136. 3-Adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation (2005) 111 3429 3434.
137. 2-Adrenergic receptor gene variations associated with stage-2 hypertension in northern Han Chinese. Ann. Hum. Genet. (2005) 69 36 44.
138. 2-adrenergic receptor gene is associated with essential hypertension in a population of Chinese origin. Am. J. Hypertens. (2001) 14 1196 1200.
139. 2-Adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: the Bergen Blood Pressure Study. Kidney Int. (1998) 53 1455 1460.
140. 2- Adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes. Hypertension (2001) 37 1303 1308.
141. 2- Adrenergic receptor gene variations, blood pressure, and heart size in normal twins. Hypertension (2000) 35 555 560.
142. Jindra A., Horky K., Peleska J. et al. Association analysis of Arg16Gly polymorphism of the beta2-adrenergic receptor gene in offspring from hypertensive and normotensive families. Blood Press. (2002) 11 213 217.
143. 2- adrenergic receptor gene with essential hypertension in the non-Han Chinese Yi minority population. J. Hypertens. (2006) 24 1041 1047.
144. 2 receptor in a Swedish hypertensive population. J. Hum. Hypertens. (2005) 19 705 708.
145. Sehti A.A., Tybjaerg-Hansen A., Jensen G.B., Nordestgaard B.G. 164Ile allele in the β2-adrenergic receptor gene is associated with risk of elevated blood pressure in women. The Copenhagen City Heart Study. Pharmacogenet. Genomics (2005) 15 633 645.
146. 2-Adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians. J. Hypertens. (2000) 18 687 693.
147. 2-adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies. J. Hypertens. (2002) 20 229 235.
148. 2-adrenergic receptor gene: linkage and association analysis. Hypertension (2002) 40 286 291.
149. 2 adrenergic receptor increases the risk of cardiac hypertrophy in hypertension. J. Hypertens. (2004) 22 2117 2122.
150. Galletti F., Icone R., Ragone E. et al. Lack of association between polymorphism in the beta2-adrenergic receptor gene, hypertension, and obesity in the Olivetti heart study. Am. J. Hypertens. (2004) 17 718 720.
151. 2-Adrenergic
152. 2- Adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly. Circulation (2003) 107 2021 2024.
153. 2- Adrenergic receptor polymorphisms and determinants of cardiovascular risk: the Cardiovascular Health Study. Am. J. Hypertens. (2005) 18 392 397.
154. 2-adrenoceptor haplotypes and age on susceptibility to hypertension and receptor function. Hypertension (2005) 46 301 307.
155. 2- Adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential hypertension in Whites and African Americans. Am. J. Hypertens. (2000) 13 1021 1026.
156. 2- adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans. Clin. Pharmacol. Ther. (2000) 67 670 675.
157. 2 adrenoceptor polymorphisms with hypertension in a Black African population. J. Hypertens. (2000) 18 167 172.
158. 2-adrenergic receptor polymorphisms with hypertension in Japanese. Hypertension (2001) 37 286 292.
159. Lee Y.-W., Oh V.M.S., Garcia E. et al. Haplotypes of the β2-adrenergic receptor gene are associated with essential hypertension in a Singaporean Chinese population. J. Hypertens. (2004) 22 2111 2116.
160. Communal C., Singh K., Sawyer D.B., Colucci W.S. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G-protein. Circulation (1999) 100 2210 2212.
161. 2-adrenoceptors in hypertrophic and apoptotic effects of noradrenaline and adrenaline in adult rat ventricular cardiomyocytes. Naunyn-Schmiedebergs Arch. Pharmacol. (2003) 367 592 599.
162. Xiao R.-P., Zhu W., Zheng M. et al. Subtype-specific β-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol. Sci. (2004) 25 358 365.
163. Molenaar P., Parsonage W.A. Fundamental considerations of β-adrenoceptor subtypes on human heart failure. Trends Pharmacol. Sci. (2005) 26 368 375.
164. Brodde O.-E., Bruck H., Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J. Pharmacol. Sci. (2006) 100 323 337.
165. 2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J. Clin. Invest. (1998) 102 1534 1539.
166. 2-Adrenergic receptor genotype and survival among patients receiving β-blocker therapy after an acute coronary syndrome. JAMA (2005) 294 1526 1533.
167. Sotoodehnia N., Siscovick D.S., Vatta M. et al. β2-Adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation (2006) 113 1842 1848.
168. Kaye D.M., Smirk B., Williams C., Jennings G., Esler M., Host D. β-Adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics (2003) 13 379 382.
169. Metra M., Nodari S., Pezzali N. et al. Beta-2 adrenergic receptors polymorphisms influence the effects of carvedilol in the patients with chronic heart failure. Eur. J. Heart Fail. (2007) 6 (Suppl. 1 100 (Abstract).
170. 2-adrenoceptor polymorphism for the outcome of chronic heart failure? Basic Res. Cardiol. (2006) 101 479 484.
171. 2-adrenergic receptor determine exercise capacity in patients with heart failure. Circ. Res. (2000) 86 834 840.
172. Zee R.Y.L., Cook N.R., Reynolds R., Cheng S., Ridker P.M. Haplotype analysis of the β2 adrenergic receptor gene and risk of myocardial infarction in humans. Genetics (2005) 169 1583 1587.